{"id": "641ad941690f196b5100003d", "sentence1": "Are LOQ and LOD the same?", "sentence2": "The limit of detection (LoD) and limit of quantitation (LoQ)  Missing values caused by the limit of detection or quantification (LOD/LOQ) were widely observed in mass spectrometry Limits of detection (LOD) and quantification (LOQ) at 10 and 20\u2009ng/g were achieved, The quantitative parameters of sensor for silver ion are determined as the limit of detection (LOD) 5.95\u00a0\u00d7\u00a010-7 M, and limit of quantitation (LOQ) 1.98\u00a0\u00d7\u00a010-8 M in the linear range", "label": "no"}
{"id": "64179337690f196b51000034", "sentence1": "Do machine learning-based methods outperform statistical methods for survival analysis?", "sentence2": "Our results reveal that machine-learning-based models such as random survival forests, gradient boosted survival model, and survival support vector machine can outperform the traditional statistical methods, i.e., Cox proportional hazard model. DeepSurv models consistently outperformed CoxPH; both approaches performed best when provided with all the datasets.", "label": "yes"}
{"id": "6402c868201352f04a00000b", "sentence1": "Was erythropoietin effective for optic neuritis in the TONE trial?", "sentence2": "INTERPRETATION: Erythropoietin as an adjunct to corticosteroids conveyed neither functional nor structural neuroprotection in the visual pathways after optic neuritis.", "label": "no"}
{"id": "64299b6a57b1c7a315000001", "sentence1": "Is COVID-19 caused by the Omicron variant less severe than infection caused by other variants?", "sentence2": "Omicron appears to lead to a milder illness for patients compared with previous COVID-19 variants. Most of those infected with Omicron experience symptoms, and the Omicron variant appears to lead to less severe disease. However, this does not mean that all the infected experience an Omicron infection as mild. In this study, symptoms of COVID-19 tended to be milder than described for previous SARS-CoV2 variants. These early national data suggest that omicron is associated with a two-thirds reduction in the risk of COVID-19 hospitalisation compared with delta. Globally, SARS CoV-2 omicron variant has led to a notable increase of COVID-19 diagnoses, although with less severe clinical manifestations and decreased hospitalizations. One of the newest variants is Omicron, which shows an increase in its transmissibility, but also reportedly reduces hospitalization rates and shows milder symptoms, such as in those who have been vaccinated. Here we compared 3-day risks of emergency department (ED) visit, hospitalization, intensive care unit (ICU) admission, and mechanical ventilation in patients who were first infected during a time period when the Omicron variant was emerging to those in patients who were first infected when the Delta variant was predominant. First time SARS-CoV-2 infections occurring at a time when the Omicron variant was rapidly spreading were associated with significantly less severe outcomes than first-time infections when the Delta variant predominated. After propensity-score matching for demographics, socio-economic determinants of health, comorbidities, medications and vaccination status, the 3-day risks in the Emergent Omicron cohort outcomes were consistently less than half those in the Delta cohort: ED visit: 4.55% vs. 15.22% (risk ratio or RR: 0.30, 95% CI: 0.28-0.33); hospitalization: 1.75% vs. 3.95% (RR: 0.44, 95% CI: 0.38-0.52]); ICU admission: 0.26% vs. 0.78% (RR: 0.33, 95% CI:0.23-0.48); mechanical ventilation: 0.07% vs. 0.43% (RR: 0.16, 95% CI: 0.08-0.32). The Omicron is highly transmissible and is spreading faster than any previous variant, but may cause less severe symptoms than previous variants. The omicron variant (B.1.1.529) of SARS-CoV-2 has demonstrated partial vaccine escape and high transmissibility, with early studies indicating lower severity of infection than that of the delta variant (B.1.617.2). We aimed to better characterise omicron severity relative to delta by assessing the relative risk of hospital attendance, hospital admission, or death in a large national cohort. The adjusted hazard ratio (HR) of hospital attendance (not necessarily resulting in admission) with omicron compared with delta was 0\u00b756 (95% CI 0\u00b754-0\u00b758); for hospital admission and death, HR estimates were 0\u00b741 (0\u00b739-0\u00b743) and 0\u00b731 (0\u00b726-0\u00b737), respectively.  The risk of severe outcomes following SARS-CoV-2 infection is substantially lower for omicron than for delta, with higher reductions for more severe endpoints and significant variation with age. The Omicron variant (B.1.1.529) is estimated to be more transmissible than previous strains of SARS-CoV-2 especially among children, potentially resulting in croup which is a characteristic disease in children. A significant difference between the age-specific susceptibility to the Omicron and that to the pre-Omicron variants was found in the younger age group. The rise in susceptibility to the Omicron/pre-Delta variant was highest in the 10-15 years age group (5.28 times [95% CI, 4.94-5.60]), and the rise in susceptibility to the Omicron/Delta variant was highest in the 15-19 years age group (3.21 times [95% CI, 3.12-3.31]), whereas in those aged 50 years or more, the susceptibility to the Omicron/pre-Omicron remained stable at approximately twofold. Even after adjusting for contact pattern, vaccination status, and waning of vaccine effectiveness, the Omicron variant of SARS-CoV-2 tends to propagate more easily among children than the pre-Omicron strains.", "label": "yes"}
{"id": "64040bd8201352f04a00000e", "sentence1": "Should be used bexarotene for relapsing-remitting multiple sclerosis?", "sentence2": "INTERPRETATION: We do not recommend the use of bexarotene to treat patients with multiple sclerosis because of its poor tolerability and negative primary efficacy outcome.", "label": "no"}
{"id": "6429ee7457b1c7a31500000b", "sentence1": "Can analgesics or antipyretics be taken for side effects following COVID-19 vaccination?", "sentence2": "Analgesics or antipyretic medications are often used to alleviate vaccine side effects, but their effect on immunogenicity remains uncertain. Few studies have assessed the effect of analgesics/antipyretics on vaccine immunogenicity and reactogenicity. Some studies revealed changes in certain immune response parameters post-vaccination when analgesics/antipyretics were used either prophylactically or therapeutically. Still, there is no evidence that these changes impact vaccine efficacy. Specific data on the impact of analgesic/antipyretic medications on immunogenicity of COVID-19 vaccines are limited. However, available data from clinical trials of licensed vaccines, along with recommendations from public health bodies around the world, should provide reassurance to both healthcare professionals and vaccine recipients that short-term use of analgesics/antipyretics at non-prescription doses is unlikely to affect vaccine-induced immunity.  Although fever is part of the normal inflammatory process after immunisation, prophylactic antipyretic drugs are sometimes recommended to allay concerns of high fever and febrile convulsion. We assessed the effect of prophylactic administration of paracetamol at vaccination on infant febrile reaction rates and vaccine responses.  Although febrile reactions significantly decreased, prophylactic administration of antipyretic drugs at the time of vaccination should not be routinely recommended since antibody responses to several vaccine antigens were reduced. Antibody geometric mean concentrations (GMCs) were significantly lower in the prophylactic paracetamol group than in the no prophylactic paracetamol group after primary vaccination for all ten pneumococcal vaccine serotypes, protein D, antipolyribosyl-ribitol phosphate, antidiphtheria, antitetanus, and antipertactin. Worldwide, paracetamol is administered as a remedy for complaints that occur after vaccination. Recently published results indicate that paracetamol inhibits the vaccination response in infants when given prior to vaccination. One month after the second booster vaccination, the anti-HBs level in the prophylactic paracetamol group was significantly lower (p = 0.048) than the level in the control group (4257 mIU/mL vs. 5768 mIU/mL). The anti-HBs level in the therapeutic paracetamol group (4958 mIU/mL) was not different (p = 0.34) from the level in the control group. Only prophylactic paracetamol treatment, and not therapeutic treatment, during vaccination has a negative influence on the antibody concentration after hepatitis B vaccination in adults. These findings prompt to consider therapeutic instead of prophylactic treatment to ensure maximal vaccination efficacy and retain the possibility to treat pain and fever after vaccination.", "label": "no"}
{"id": "64281a47690f196b5100004f", "sentence1": "Is OXLUMO (lumasiran) used for the treatment of primary hyperoxaluria?", "sentence2": "Lumasiran (Oxlumo\u2122) is a subcutaneously administered small interfering RNA (siRNA) targeting the mRNA for hydroxyacid oxidase 1 gene (HAO1; encodes glycolate oxidase) and was developed by Alnylam Pharmaceuticals for the treatment of primary hyperoxaluria type 1 (PH1). OXLUMO (lumasiran) for the treatment of primary hyperoxaluria,", "label": "yes"}
{"id": "6429cfb557b1c7a315000005", "sentence1": "Should patients using inhaled glucocorticoids for asthma or COPD be advised to stop these medications to prevent COVID-19?", "sentence2": "International recommendations suggest maintaining asthma under control to limit exacerbations occurrence, by using all available treatment. The minimum steroid dosage effective to control symptoms should be maintained to avoid exacerbations; The meta-analysis revealed no significant difference in the risk for the development of a fatal course of COVID-19 with preadmission use of inhaled corticosteroids in patients with COVID-19 relative to non-use of inhaled corticosteroids (pooled odds ratio=1.28; 95% confidence interval 0.73-2.26). Similarly, the meta-analysis observed no significant difference in the risk for the development of a severe course of COVID-19 with preadmission use of inhaled corticosteroids in patients with COVID-19 relative to non-use of inhaled corticosteroids (pooled odds ratio=1.45; 95% confidence interval 0.96-2.20). Our findings assured the safety of continued use of inhaled corticosteroids during the COVID-19 pandemic. Our study showed that asthma is not associated with worse outcomes of COVID-19, despite the higher need for respiratory support compared with the general population, while the use of ICS allowed for a shorter hospital stay. Patients with asthma in regular therapy with ICS at home had significantly shorter hospital stay compared to those with no treatments (25.2 vs. 11.3 days, p = 0.024). Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19.", "label": "no"}
{"id": "6432f75757b1c7a31500001d", "sentence1": "Is Zanubrutinib a first-generation BTK inhibitor approved by US Food and Drug Administration (FDA)?", "sentence2": "In the United States, zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle cell lymphoma who have received at least one prior therapy, for adults with Waldenstr\u00f6m macroglobulinemia, and for adults with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based therapy.", "label": "no"}
{"id": "63eef94ff36125a426000010", "sentence1": "Is Cinpanemab effective for Parkinson\u2019s Disease?", "sentence2": "CONCLUSIONS: In participants with early Parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in DaT-SPECT imaging did not differ from those of placebo over a 52-week period.", "label": "no"}
{"id": "643306cc57b1c7a315000027", "sentence1": "Can CRISPR/Cas12a be used for the detection of EGFR mutations in circulating DNA?", "sentence2": "A CRISPR Test for Rapidly and Sensitively Detecting Circulating EGFR Mutations. The CRISPR-Cas12a system can detect both L858R and T790M with a limit of detection of 0.005% in less than three hours. The CRISPR-Cas12a system could detect L858R in plasma of two lung cancer patients whose tissue biopsies are positive for L858R, and one plasma sample of three lung cancer patients whose tissue biopsies are positive for T790M.   This proof of principle study demonstrates that the CRISPR-Cas12a system could rapidly and sensitively detect circulating EGFR mutations, and thus, has potential prognostic or therapeutic implications.", "label": "yes"}
{"id": "63f9ccdc33942b094c00000f", "sentence1": "Is PRP-40 involved in microexon splicing?", "sentence2": "PRP-40 is particularly required for inclusion of neuronal microexons, and our data indicate that PRP-40 is a central regulator of microexon splicing. Microexons can be relieved from PRP-40 dependence by artificially increasing exon size or reducing flanking intron size, indicating that PRP-40 is specifically required for microexons surrounded by conventionally sized introns. Knockdown of the orthologous PRPF40A in mouse neuroblastoma cells causes widespread dysregulation of microexons but not conventionally sized exons. PRP-40 regulation of neuronal microexons is therefore a widely conserved phenomenon.", "label": "yes"}
{"id": "6404199d201352f04a000019", "sentence1": "Is ocrelizumab effective for primary progressive multiple sclerosis?", "sentence2": "Ocrelizumab (Ocrevus\u00ae) is an intravenously administered, humanized anti-CD20 monoclonal antibody approved for the treatment of adults with relapsing forms of multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). When using the anti-CD20 monoclonal antibodies ocrelizumab and ofatumumab in the treatment of MS, it is not necessary to test for NAbs as these occur very infrequently.  Ocrelizumab for multiple sclerosis. BACKGROUND: Ocrelizumab is a humanised anti-CD20 monoclonal antibody developed for the treatment of multiple sclerosis (MS). It was approved by the Food and Drug Administration (FDA) in March 2017 for using in adults with relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS).", "label": "no"}
{"id": "63f9cdcc33942b094c000013", "sentence1": "Does silencing of SRRM4 inhibit tumor growth across cancers?", "sentence2": "Silencing of SRRM4 suppresses microexon inclusion and promotes tumor growth across cancers. We show that this silencing is favorable for tumor growth, as decreased SRRM4 expression in tumors is correlated with an increase in mitotic gene expression, and up-regulation of SRRM4 in cancer cell lines dose-dependently inhibits proliferation in vitro and in a mouse xenograft model. Further, this proliferation inhibition is accompanied by induction of neural-like expression and splicing patterns in cancer cells, suggesting that SRRM4 expression shifts the cell state away from proliferation and toward differentiation. We therefore conclude that SRRM4 acts as a proliferation brake, and tumors gain a selective advantage by cutting off this brake.", "label": "no"}
{"id": "64041e97201352f04a00001e", "sentence1": "Is daridorexant effective for insomnia?", "sentence2": "Daridorexant (Quviviq\u2122; Idorsia Pharmaceuticals Ltd.) is an orally administered dual orexin type 1 and type 2 (OX1 and OX2) receptor antagonist (DORA) being developed for the treatment of insomnia. Daridorexant was superior to placebo in reducing wake time after sleep onset (MD\u2009=\u2009-13.26; 95% CI, -15.48 to -11.03; P\u2009<\u20090.00001), latency to persistent sleep (MD\u2009=\u2009-7.23; 95% CI, -9.60 to -4.85; P\u2009<\u20090.00001), with increasing the total sleep time (MD\u2009=\u200914.80; 95% CI, 11.18-18.42; P\u2009<\u20090.00001) and subjective total sleep time (MD\u2009=\u200914.80; 95% CI, 11.18-18.42], P\u2009<\u20090.00001). The 25 mg and 50 mg were the most officious doses. Treatment with daridorexant has resulted in a slightly higher incidence of adverse events [risk ratio (RR)\u2009=\u20091.19; 95% CI, 1.05-1.35;, P\u2009=\u20090.005], specifically somnolence (RR\u2009=\u20091.19; 95% CI, 1.13-3.23; P\u2009=\u20090.005) and fatigue (RR\u2009=\u20092.01; 95% CI, 1.21-3.36; P\u2009=\u20090.007). Daridorexant is superior to placebo in improving sleep quality.", "label": "yes"}
{"id": "64041dae201352f04a00001d", "sentence1": "Is deucravacitinib effective for psoriasis?", "sentence2": "POETYK PSO-1 and PSO-2 involved 1688 patients with moderate-to-severe psoriasis. After 16\u00a0weeks, in both studies, over 50% of patients treated with deucravacitinib reached PASI75, which was significantly superior to placebo and apremilast. In POETYK PSO-1, these results improved until week 24 and were maintained through week 52, with over 65% of patients achieving PASI75 at this point. A reduction in signs and symptoms was also reported by patients, with greater impact on itch. Deucravacitinib was well tolerated and safe.  INTRODUCTION: Deucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that demonstrated therapeutic benefit in a Phase 2 clinical trial of adults with moderate to severe plaque psoriasis.  CONCLUSION: Deucravacitinib treatment produced early response and similar trends in improvements across multiple efficacy assessments and QoL in moderate to severe plaque psoriasis.  CONCLUSION: Deucravacitinib was superior to placebo and apremilast across multiple efficacy endpoints and was well tolerated in moderate to severe psoriasis.", "label": "yes"}
{"id": "6428da47690f196b51000051", "sentence1": "Can the epigenetic status of introns affect gene expression?", "sentence2": "Here, we show that the expression of the H3K9 demethylase IBM1 (increase in BONSAI methylation 1) requires DNA methylation. Surprisingly, the regulatory methylated region is contained in an unusually large intron that is conserved in IBM1 orthologues. DNA methylation in an intron of the IBM1 histone demethylase gene stabilizes chromatin modification patterns. Polyadenylation (poly(A) sequencing reveals that AAE complex has a substantial influence on poly(A) site usage of heterochromatin-containing genes, including not only intronic heterochromatin-containing genes but also the genes showing overlap with heterochromatin. Heterochromatin is widespread in eukaryotic genomes and has diverse impacts depending on its genomic context. Combining methylation data with mRNA sequencing revealed that DNA methylation in promoters, introns and exons may have different roles in regulating gene expression. In several eukaryotic organisms, heterochromatin (HC) in the introns of genes can regulate RNA processing, including polyadenylation, but the mechanism underlying this regulation is poorly understood. Here we report that ASI1 and EDM2 form a protein complex in vivo via a bridge protein, ASI1-Immunoprecipitated Protein 1 (AIPP1), which is another RNA recognition motif-containing protein. The complex also may contain the Pol II CTD phosphatase CPL2, the plant homeodomain-containing protein AIPP2, and another BAH domain protein, AIPP3. As is the case with dysfunction of ASI1 and EDM2, dysfunction of AIPP1 impedes the use of distal polyadenylation sites at tested intronic HC-containing genes, such as the histone demethylase gene IBM1, resulting in a lack of functional full-length transcripts.", "label": "yes"}
{"id": "642d4c9b57b1c7a315000013", "sentence1": "Are Luminopsins a fusion proteins of luminol and Rhodopsin ?", "sentence2": "Bioluminescence-optogenetics is mediated by luminopsin fusion proteins-light-sensing opsins fused to light-emitting luciferases. Here we have expanded and refined the versatility of luminopsin tools by fusing an alternative luciferase variant with high light emission, Gaussia luciferase mutant GLucM23, to depolarizing and hyperpolarizing channelrhodopsins  luminopsins by fusing light-sensing opsins with light-emitting luciferases.  ouse iPS-NPCs were transduced with a novel optochemogenetics fusion protein, luminopsin 3 (LMO3), which consisted of a bioluminescent luciferase, Gaussia luciferase, and an opsin, Volvox Channelrhodopsin 1.", "label": "yes"}
{"id": "6428da98690f196b51000053", "sentence1": "Is there a way to distinguish COVID-19 clinically from other respiratory illnesses, such as influenza?", "sentence2": "Unfortunately, COVID-19 patients have symptoms similar to other common illnesses. Here, we hypothesize the order of symptom occurrence could help patients and medical professionals more quickly distinguish COVID-19 from other respiratory diseases, yet such essential information is largely unavailable. No symptoms are characteristic of a single infectious agent, with flu-like disorders being the most common. We show that although COVID-19 and influenza are different in many ways, there are numerous similarities; thus, in addition to using nucleic acid-based polymerase chain reaction (PCR) and antibody-based approaches, clinicians and epidemiologists should distinguish between the two using their respective characteristics in early stages. An understanding of differences in clinical phenotypes and outcomes COVID-19 compared with other respiratory viral infections is important to optimise the management of patients and plan healthcare. SARS-CoV-2 is associated with more severe outcomes compared with other respiratory viruses, and although associated with specific patient and clinical characteristics at admission, a substantial overlap precludes discrimination based on these characteristics.", "label": "yes"}
{"id": "6428d7da690f196b51000050", "sentence1": "Can untranslated regions (UTRs) regulate gene expression?", "sentence2": "Previously dismissed as \"junk DNA\", it is the non-coding regions of the genome that are responsible for regulation, facilitating complex temporal and spatial gene expression through the combinatorial effect of numerous mechanisms and interactions working together to fine-tune gene expression. The major regions involved in regulation of a particular gene are the 5' and 3' untranslated regions and introns. Post-transcriptional regulation, via 5'-UTRs (5'-untranslated regions), plays an important role in the control of eukaryotic gene expression. Eukaryotic gene expression is precisely regulated at all points between transcription and translation. In this review, we focus on translational control mediated by the 3'-untranslated regions (UTRs) of mRNAs. mRNA 3'-UTRs contain cis-acting elements that function in the regulation of protein translation or mRNA decay. Now, we are beginning to better appreciate the role of 3'-UTR (untranslated region) cis-elements which harbor not only microRNA but also RNA-binding protein (RBP) binding sites that have significant effect on the stability and translational rate of mRNAs. Many studies using reporter assays have demonstrated that 3' untranslated regions (3'-UTRs) regulate gene expression by controlling mRNA stability and translation.", "label": "yes"}
{"id": "63f9cbb433942b094c00000c", "sentence1": "Is alternative splicing associated with heart disease?", "sentence2": "We identified >200 significant alternative splicing (AS) events and distinct AS profiles were observed in the right (RV) and left (LV) ventricles in PLN-R14del compared to WT mouse hearts.  Our findings suggest that aberrant splicing may affect Ca2+-homeostasis in the heart, contributing to the increased risk of arrythmogenesis in PLN-R14del ACM.", "label": "yes"}
{"id": "61fa941ec9dfcb9c09000005", "sentence1": "Should Intepirdine be used for Alzheimer's disease?", "sentence2": "There were no statistically significant differences between intepirdine and placebo groups (adjusted mean [95% confidence interval]) on the co-primary endpoints ADAS-Cog (-0.36 [-0.95, 0.22], P\u00a0=\u00a00.2249) and ADCS-ADL (-0.09 [-0.90, 0.72], P\u00a0=\u00a00.8260).  Discussion: Intepirdine as adjunctive therapy to donepezil did not produce statistical improvement over placebo on cognition or activities of daily living in mild-to-moderate AD dementia patients. EXPERT OPINION: Despite early positive findings, larger phase-III trials have failed to demonstrate any statistically significant impact on cognition for both idalopirdine and intepirdine, as adjunct to cholinesterase inhibitors.", "label": "no"}
{"id": "61f7cb37882a024a10000029", "sentence1": "Is rilonacept effective for pericarditis?", "sentence2": "Concerning acute recurrent pericarditis (RP), an innovative interaction between cardiologists, internists and pediatric rheumatologists led to the intuition of a pivotal role of IL-1 in recurrent pericarditis characterized by an evident inflammatory recurrent phenotype, and recent data have shown the striking efficacy of anakinra and rilonacept in these patients.  Pericarditis is regarded as a stereotypical response to an acute damage of the mesothelial cells of the pericardial layers. NLRP3 inflammasome, a macromolecular structure sensing damage and releasing pro-inflammatory cytokines, is centrally involved as it releases interleukin (IL)-1\u03b2, whose auto-induction feeds an autoinflammatory disease, mostly responsible for recurrences. Colchicine, an inhibitor of NLRP3 inflammasome formation, and IL-1-targeted therapies, such as anakinra and rilonacept, were found to effectively blunt the acute inflammation and reduce the risk for recurrences. Currently, anakinra and rilonacept, have demonstrated beneficial impact in clinical outcomes with a reasonable safety profile in randomized clinical trials. There is still paucity of data regarding the use of canakinumab in the treatment of patients with RP.  Rilonacept: A Newly Approved Treatment for Recurrent Pericarditis. OBJECTIVE: To review the pharmacology, efficacy, and safety of rilonacept for the prevention and treatment of recurrent pericarditis (RP). CONCLUSION: Rilonacept is a safe, once weekly, subcutaneously administered IL-1 \"trap,\" indicated for the treatment of RP, and reduction in risk of recurrent pericarditis in adults and children \u226512 years of age. Overproduction of both IL-1\u03b1 (released by inflamed/damaged pericardial cells) and IL-1\u03b2 (released by inflammatory cells) is now a well-recognized therapeutic target in patients with recurrent idiopathic pericarditis. Currently, there are three available anti-IL-1 agents: anakinra (recombinant human IL-1Ra), rilonacept (a soluble decoy receptor 'trap', binding both IL-1\u03b1 and IL-1\u03b2), and canakinumab (human monoclonal anti-IL-1\u03b2 antibody).", "label": "yes"}
{"id": "64041f38201352f04a00001f", "sentence1": "Is tebentafusp effective for uveal melanoma?", "sentence2": "Tebentafusp (tebentafusp-tebn; Kimmtrak\u00ae) is a first-in-class, bispecific gp100 peptide-HLA-A*02:01 directed T cell receptor (TCR) CD3 T cell engager being developed by Immunocore for the treatment of uveal melanoma and malignant melanoma.  This article summarizes the milestones in the development of tebentafusp leading to this first approval for unresectable or metastatic uveal melanoma. Tebentafusp was granted full approval on January 25th 2022 in the setting of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. In a large meta-analysis, surgical treatment was associated with 6 months longer median overall survival as compared to conventional chemotherapy and, recently, tebentafusp as first-line treatment at the first interim analysis of a randomized phase III trial likewise provided a 6 months longer median overall survival compared to investigator's choice, mostly pembrolizumab; these treatments currently apply to selected patients.", "label": "yes"}
